Active Ingredient(s):Moxetumomab Pasudotox-tdfk FDA Approved: * September 13, 2018 Pharm Company: *ASTRAZENECA AB Category:Cancer
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consist...
* May have multiple approval dates, manufacturers, or labelers.
Lumoxiti 1 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution